4th Quarter - Report

MEHLMAN CONSULTING, INC. for ASTRAZENECA PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

International trade issues, including free-trade agreements; import safety.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax issues, including repatriation, deferral and carried interest.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Health care reform law (PL 111-148) -- implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.